Tiotropium/Corticosteroid/Beta Agonist Combo Increases Survival in COPD Patients

The popular anticholinergic bronchodilator, tiotropium (aka Spiriva) is in the spotlight again with good news for COPD patients. In a study conducted by the University of Illinois at Chicago (UIC), Todd Lee, associate professor of pharmacy practice, and his research team compared over 42,000 cases of COPD patients both two and a half years prior to tiotropium's 2004 entry into the marketplace and two and a half years after.

Results of the study concluded that patients who were treated with tiotropium plus an inhaled corticosteroid and a long-acting beta-agonist lived longer and had fewer COPD-related hospital stays.

Anticholinergic and beta agonist bronchodilators help relax the airways making it easier to breathe. Corticosteroids help reduce swelling and inflammation in the airways which also helps relieve shortness of breath.

Previous studies performed on tiotropium have been in the context of clinical trials and showed that the drug improves lung function, COPD symptoms and quality of life, Lee said. But while evidence on the efficacy of the drug accumulates through prospective trials, Lee said it is important to examine outcomes in look-back studies because the patient populations may be vastly different.

How Does This Information Benefit You?

As a COPD patient, knowing the latest information about COPD treatment will empower you to take part in your own plan of care. As a patient, you have every right to fully understand the plan of care that has been prescribed for you, and question any part of it that you either don't understand or don't agree with. The next time you visit your doctor, talk to him about the results of this study to determine if your current medication schedule needs an adjustment. Working with your doctor will give you a better sense of control over your life and help you make the right decisions about your health care.